Phase 2 Prostate Cancer Trial, Recruiting NCT03079323 Sponsor: Universitaire Ziekenhuizen KU Leuven Condition: Prostate Cancer
Back to Prostate Cancer

Phase 2 Prostate Cancer Trial, Recruiting

NCT03079323
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are willing to sign a consent form and follow the treatment and follow-up schedule
  • People who have been diagnosed with prostate cancer confirmed by a tissue sample (biopsy or surgery)
  • People who have not received any previous treatment for prostate cancer
  • People whose cancer has been found in nearby lymph nodes after an extended lymph node removal surgery, meeting specific criteria defined in the trial protocol (confirm with trial site)
  • People aged 18 or older
  • People with a general health and activity level above a certain threshold, as measured by a standard medical scoring system (confirm with trial site)
  • People who are able to understand the information given about the trial

Who may not be able to join:

  • People whose prostate cancer has come back after a previous period of being cancer-free
  • People whose cancer has already spread to distant parts of the body, such as distant lymph nodes, bones, or other organs
  • People who have had previous radiation therapy in a way that would make the radiation treatments in this trial impossible to deliver safely
  • People who have had another type of cancer in the past, unless they have been cancer-free for more than 5 years (an exception may apply for a common, low-risk type of skin cancer — confirm with trial site)
  • People with serious or active health conditions that could make it unsafe or impractical to receive the radiation treatments used in this trial
  • People who have a condition that prevents them from understanding trial information

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Gert De Meerleer, Prof. Dr., UZ Leuven

Phone: 00 32 16 34 76 00

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Registry
ClinicalTrials.gov
Start date
6 February 2017
Est. completion
1 February 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Clinical relapse-free survival (cRFS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov